Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 33, 2022 - Issue 4
Submit an article Journal homepage
8,270
Views
17
CrossRef citations to date
0
Altmetric
Articles

Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study

Andrew Blauvelta Oregon Medical Research Center, Portland, OR, USAORCID Iconhttps://orcid.org/0000-0002-2633-985XView further author information
ORCID Icon,
April W. Armstrongb Keck School of Medicine, University of Southern California, Los Angeles, CA, USAORCID Iconhttps://orcid.org/0000-0003-0064-8707View further author information
ORCID Icon,
Richard G. Langleyc Department of Medicine, Dalhousie University, Halifax, NS, CanadaView further author information
,
Kurt Gebauerd Fremantle Dermatology, Fremantle, Australia;e Probity Medical Research, Waterloo, Ontario, CanadaView further author information
,
Diamant Thaçif The Institute and Comprehensive Center Inflammation for Medicine, University of Lübeck, Lübeck, GermanyORCID Iconhttps://orcid.org/0000-0001-8513-550XView further author information
ORCID Icon,
Jerry Bagelg The Psoriasis Treatment Center of Central New Jersey, East Windsor, NJ, USAORCID Iconhttps://orcid.org/0000-0001-5241-0915View further author information
ORCID Icon,
Lyn C. Guentherh Guenther Research Inc, London, ON, CanadaORCID Iconhttps://orcid.org/0000-0001-9286-1534View further author information
ORCID Icon,
Carle Pauli Toulouse University and CHU Hôpital Larrey, Toulouse, FranceORCID Iconhttps://orcid.org/0000-0003-0165-5263View further author information
ORCID Icon,
Bruce Randazzoj Janssen Research & Development, LLC, Spring House, PA, USAORCID Iconhttps://orcid.org/0000-0002-0773-0263View further author information
ORCID Icon,
Susan Flavinj Janssen Research & Development, LLC, Spring House, PA, USAORCID Iconhttps://orcid.org/0000-0002-5587-4552View further author information
ORCID Icon,
Ming-Chun Hsuj Janssen Research & Development, LLC, Spring House, PA, USAORCID Iconhttps://orcid.org/0000-0003-1527-3135View further author information
ORCID Icon,
Yin Youj Janssen Research & Development, LLC, Spring House, PA, USAORCID Iconhttps://orcid.org/0000-0001-7741-9270View further author information
ORCID Icon &
Kristian Reichk Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, GermanyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-5248-4332View further author information
ORCID Icon show all
Pages 2317-2324 | Received 15 Jun 2021, Accepted 19 Jul 2021, Published online: 04 Aug 2021

Citations (17)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Lluís Rusiñol, Elena Carmona-Rocha & Lluís Puig. (2024) Durability and long-term outcomes of biologic therapies in psoriasis. Expert Review of Clinical Immunology 20:1, pages 71-82.
Read now

Articles from other publishers (16)

Edinson López, Raúl Cabrera & Cristóbal Lecaros. (2024) Targeted therapy for immune mediated skin diseases. What should a dermatologist know?. Anais Brasileiros de Dermatologia 99:4, pages 546-567.
Crossref
Enikö Sonkoly, Julia-Tatjana Maul, Matteo Megna, Patricia Gorecki, Edmée Crombag, Jozefien Buyze & Laura Savage. (2024) Guselkumab in Patients with Scalp Psoriasis: A post hoc Analysis of the VOYAGE 2 Phase III Randomized Clinical Trial. Acta Dermato-Venereologica 104, pages adv18672.
Crossref
Xiaojun Shi, Keke Li & Chen Li. (2023) Is anti‐IL‐17 faster and anti‐IL‐23 better for psoriasis patients after adalimumab failure?. JEADV Clinical Practice 3:1, pages 331-332.
Crossref
Marco Galluzzo, Lorenzo Marcelli, Angela Fico, Luca Bianchi & Marina Talamonti. (2023) Successful long‐term guselkumab treatment of severe plaque psoriasis in patients with class III obesity: A case series. Skin Health and Disease 4:1.
Crossref
Lluís Rusiñol & Lluís Puig. (2024) Multi-Omics Approach to Improved Diagnosis and Treatment of Atopic Dermatitis and Psoriasis. International Journal of Molecular Sciences 25:2, pages 1042.
Crossref
James Krueger, Richard G. Langley, Simon Nigen, Torben Kasparek, Gabriele Di Comite, Christine‐Elke Ortmann, Sandra Garcet, Frank Kolbinger & Kristian Reich. (2023) Secukinumab versus guselkumab in the complete resolution of ustekinumab‐resistant psoriatic plaques: The ARROW study . Experimental Dermatology 32:10, pages 1834-1847.
Crossref
Johannes Griss, Gudrun Ratzinger, Julia‐Tatjana Maul, Wolfgang Weger, Diamant Thaçi, José Manuel Carrascosa & Constanze Jonak. (2023) No impact of disease duration on response to tildrakizumab treatment among patients with moderate‐to‐severe plaque psoriasis: Post hoc analyses from two phase 3 (reSURFACE 1 and reSURFACE 2) and one phase 4 (TRIBUTE) studies. Skin Health and Disease 3:5.
Crossref
William Tillett, Alexander Egeberg, Enikö Sonkoly, Patricia Gorecki, Anna Tjärnlund, Jozefien Buyze, Sven Wegner & Dennis McGonagle. (2023) Nail psoriasis dynamics during biologic treatment and withdrawal in patients with psoriasis who may be at high risk of developing psoriatic arthritis: a post hoc analysis of the VOYAGE 2 randomized trial. Arthritis Research & Therapy 25:1.
Crossref
Elena CARMONA-ROCHA & Lluís PUIG. (2023) The biological basis of disease recurrence in psoriasis. Italian Journal of Dermatology and Venereology 158:4.
Crossref
Emilie Sbidian, Anna Chaimani, Robin Guelimi, Ignacio Garcia-Doval, Camille Hua, Carolyn Hughes, Luigi Naldi, Maria Kinberger, Sivem Afach & Laurence Le Cleach. (2023) Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database of Systematic Reviews 2023:7.
Crossref
April W. Armstrong, Timothy Fitzgerald, Robert R. McLean, Amanda Teeple, Jonathan P. Uy, Mobolaji Olurinde, Katelyn Rowland, Lin Guo, Ying Shan & Kristina Callis Duffin. (2023) The Effectiveness of Guselkumab by BMI Category Among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry. Advances in Therapy 40:5, pages 2493-2508.
Crossref
Charles Lynde, Elisabeth Riedl, Julia-Tatjana Maul, Tiago Torres, Andreas Pinter, Gabrielle Fabbrocini, Flavia Daniele, Alan Brnabic, Catherine Reed, Stefan Wilhelm, Thorsten Holzkämper, Christopher Schuster & Luis Puig. (2022) Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Results at Week 12 from the PSoHO Study in a Real-World Setting. Advances in Therapy 40:3, pages 869-886.
Crossref
Esteban Daudén, Pablo de la Cueva, Laura Salgado-Boquete, Mar Llamas-Velasco, Eduardo Fonseca, Ignasi Pau-Charles, David Asensio, Meritxell Guilà, José Manuel Carrascosa, Mario Linares, Antonio Vélez, Mireia Yébenes, Jordi Mollet, Jesús Gardeazabal, Ángeles Flórez, José Suárez, Susana Armesto, Almudena Fernández, José Carlos Ruiz, Enrique Herrera, Lourdes Rodríguez, Mariano Ara, Gregorio Carretero, Carmen Delgado, Noemí Eiris, Carlos Ferrandiz, Lluís Puig, Ramón María Pujol, Ander Zulaica, Raquel Rivera, Natalia Jiménez, Pedro Herranz, María Carmen Fariña, Rosa María Izu, Isabel Belichón-Romero, Rafael Botella, José Luis Sánchez-Carazo, Mercè Alsina, José Luis López Estebaranz, Beatriz Pérez & Juan Ignacio Yanguas. (2022) Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: Results from a 52-Week Open-Label Phase IV Clinical Trial (DIMESKIN 1). Dermatology and Therapy 13:1, pages 329-345.
Crossref
Ricardo Ruiz‐Villaverde, Fiorella Vasquez Chinchay, Lourdes Rodriguez‐Fernandez‐Freire, Jose C. Armario‐Hita, Amalia Pérez‐Gil & Manuel Galán‐Gutiérrez. (2022) Guselkumab dosing interval optimization in adult patients with moderate‐to‐severe psoriasis switching from ustekinumab. Dermatologic Therapy 35:11.
Crossref
E. L. NasonovT. V. Korotaeva & C. F. Selmi. (2022) Prospects for the use of monoclonal antibodies to interleukin 23 Gusеlkumab in psoriatic arthritis: New data. Rheumatology Science and Practice 60:1, pages 80-90.
Crossref
Richard G. Langley, Andrew Blauvelt, April Armstrong, Ernesto J. Muñoz-Elías & Kristian Reich. (2019) Latest Highlights from Guselkumab in Psoriasis from EADV 2019. EMJ Dermatology, pages 10-16.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.